Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,255 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Triptans Clear all

Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions: Velcade, Methotrexate, Methotrexate / Hydrocortisone / Cytarabine, Dexamethasone, Mitoxantrone, Vincristine, Pegaspargase; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 1 Year to 39 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Advanced Cancer, Metastatic Cervical Cancer
Interventions: Balstilimab (BAL), Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions: everolimus, Placebo, vinorelbine, trastuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 43
States / cities: Tucson, Arizona • La Jolla, California • Greenwood Village, Colorado + 30 more

Conditions: Lymphoma
Interventions: darbepoetin alfa, filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan; Biological · Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years to 120 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2019
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Migraine Disorders
Interventions: Combination Product (sumatriptan succinate / naproxen sodium), Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 26
States / cities: Fresno, California • Newport Beach, California • Santa Monica, California + 23 more

Conditions: B-Cell Non-Hodgkin Lymphoma
Interventions: Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Rituximab, Vincristine Sulfate; Drug · Other · Biological
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: vinorelbine tartrate; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast, Cancer
Interventions: Carboplatin, Capecitabine, Vinorelbine; Drug · Device
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Leukemia
Interventions: asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, prednisone, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 9 Years
Enrollment: 1,970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2007
U.S. locations: 31
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 24 more

Conditions: Migraine
Interventions: Melatonin, Placebo oral capsule; Drug
Lead sponsor: Amy Gelfand; Other
Eligibility: 10 Years to 17 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Peripheral T Cell Lymphoma
Interventions: Golidocitinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
Interventions: Dexamethasone, Panobinostat, Liposomal vincristine, Mitoxantrone, Peg-asparaginase, Bortezomib, Intrathecal Triples, High-dose methotrexate, 6-Mercaptopurine, High-dose cytarabine, Nelarabine, Cyclophosphamide, Etoposide, Clofarabine; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma, PRETEXT IV Hepatoblastoma
Interventions: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Liver Transplantation, Temsirolimus, Therapeutic Conventional Surgery, Vincristine Sulfate; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 184
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 133 more

Conditions: Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Methotrexate, Ofatumumab, Vincristine Sulfate; Procedure · Drug · Other + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 2
States / cities: Buffalo, New York • Nashville, Tennessee

Conditions: Stuttering
Interventions: Psilocybin, Speech therapy; Drug · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Echocardiography Test, Electrocardiography, Lumbar Puncture, Mesna, Methotrexate, Multigated Acquisition Scan, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 207
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more

Conditions: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 70
States / cities: Beverly Hills, California • Fountain Valley, California • Fullerton, California + 58 more

Conditions: Lymphoblastic Lymphoma
Interventions: Vincristine, Radiation Therapy, Daunomycin, L-Asparaginase, Cytarabine, Methotrexate, Mercaptopurine, Etoposide, Cyclophosphamide, Prednisone, Dexamethasone; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2004
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Classical Hodgkin Lymphoma
Interventions: Pembrolizumab, Doxorubicin, Vinblastine, Dacarbazine, Bleomycin, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Fullerton, California • Palo Alto, California • Chicago, Illinois + 3 more

Conditions: Sleep Disorders, Hypertension
Interventions: Melatonin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 35 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Migraine With or Without Aura
Interventions: sumatriptan nasal powder, Placebo; Drug
Lead sponsor: Currax Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more

Conditions: Post-Traumatic Stress Disorder
Interventions: Yohimbine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Migraine
Interventions: Melatonin; Drug
Lead sponsor: Amy Gelfand; Other
Eligibility: 3 Years to 17 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lymphoma, Large Cell, Lymphoma, Non-Hodgkin
Interventions: Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine, Stem cell transplant,, Radiation Therapy; Drug · Procedure · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

Vinorelbine in Treating Patients With Metastatic or Advanced Solid Tumors

Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Melatonin for Adolescent Migraine Prevention Study

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

Melatonin Supplements for Improving Sleep in Individuals With Hypertension

Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) With/Without Yohimbine

CHOCOlate MeLatonin for AdolescenT MigrainE

Large Cell Lymphoma Pilot Study III